Pelitinib (BioDeep_00000766000)
代谢物信息卡片
化学式: C24H23ClFN5O2 (467.1524)
中文名称: 培利替尼, 莫立替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)C=CCN(C)C
InChI: InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
COVID info from PDB, Protein Data Bank
D000970 - Antineoplastic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:38927
- KEGGdrug: D05399
- PubChem: 6445562
- DrugBank: DB05524
- ChEMBL: CHEMBL607707
- CAS: 257933-82-7
- CAS: 326894-84-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Hadir M Maher, Nourah Z Alzoman, Shereen M Shehata, Ashwag O Abahussain. Comparative pharmacokinetic profiles of selected irreversible tyrosine kinase inhibitors, neratinib and pelitinib, with apigenin in rat plasma by UPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2017 Apr; 137(?):258-267. doi:
10.1016/j.jpba.2017.01.039. [PMID: 28167419] - Dino Luethi, Selvi Durmus, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen, Rolf W Sparidans. Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2013 Sep; 934(?):22-5. doi:
10.1016/j.jchromb.2013.06.030. [PMID: 23892825] - Csilla Hegedüs, Krisztina Truta-Feles, Géza Antalffy, György Várady, Katalin Német, Csilla Ozvegy-Laczka, György Kéri, László Orfi, Gergely Szakács, Jeffrey Settleman, András Váradi, Balázs Sarkadi. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Biochemical pharmacology.
2012 Aug; 84(3):260-7. doi:
10.1016/j.bcp.2012.04.010. [PMID: 22548830] - Dan Laheru, Gary Croghan, Ronald Bukowski, Michelle Rudek, Wells Messersmith, Charles Erlichman, Robert Pelley, Antonio Jimeno, Ross Donehower, Joseph Boni, Richat Abbas, Patricia Martins, Charles Zacharchuk, Manuel Hidalgo. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Sep; 14(17):5602-9. doi:
10.1158/1078-0432.ccr-08-0433. [PMID: 18765554] - Vicente E Torres, William E Sweeney, Xiaofang Wang, Qi Qian, Peter C Harris, Philip Frost, Ellis D Avner. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Kidney international.
2004 Nov; 66(5):1766-73. doi:
10.1111/j.1523-1755.2004.00952.x. [PMID: 15496147] - William E Sweeney, Kiyoshi Hamahira, Jennifer Sweeney, Michelle Garcia-Gatrell, Philip Frost, Ellis D Avner. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability.
Kidney international.
2003 Oct; 64(4):1310-9. doi:
10.1046/j.1523-1755.2003.00232.x. [PMID: 12969149]
